In-situ Cytokines Expression in the CNS in Amyotrophic Lateral Sclerosis (ALS)

NCT ID: NCT02582385

Last Updated: 2015-10-21

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 5 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2012-10-31
• Study Completion Date: 2015-02-28

Brief Summary

The investigators aim at exploring the differential/topographical in-situ expression of cytokines in the central nervous system (CNS) of patients who died with amyotrophic lateral sclerosis (ALS), using archived histopathology slides and residual paraffin blocks from autopsied cases. Previous studies from the investigators and other groups showed that inflammatory cytokines are implicated in several neurological affections, particularly neurodegenerative conditions. However, in-situ cytokine expression has never been studied so far in ALS. The investigators wanted to see if these neuro-mediators are involved in the neuromolecular chain/cascade underlying ALS.

Conditions

Amyotrophic Lateral Sclerosis

Study Design

• Study Time Perspective: RETROSPECTIVE

Study Groups

Amyotrophic lateral sclerosis (ALS)

Archived/residual histopathology sections and paraffin blocks, retrieved entirely from residual autopsy material from patients who died with an amyotrophic lateral sclerosis.

in-situ cytokine expression

Intervention Type: OTHER

Control

Archived/residual histopathology sections and paraffin blocks, retrieved entirely from residual autopsy material from one non-ALS case.

in-situ cytokine expression

Intervention Type: OTHER

Interventions

in-situ cytokine expression

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• patients who died with amyotrophic lateral sclerosis, having been autopsied.

Exclusion Criteria

• N/A

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Brugmann University Hospital

OTHER

Sponsor Role: lead

Responsible Party

Carine DE PREZ

Head of clinic

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Hazim Kadhim, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

CHU Brugmann

Locations

CHU Brugmann

Brussels, , Belgium

Countries

Belgium

Other Identifiers

CHUB-ALS

Identifier Type: -

Identifier Source: org_study_id